Last reviewed · How we verify

R-CHOEP 14 with 12x Rituximab

German High-Grade Non-Hodgkin's Lymphoma Study Group · Phase 3 active Small molecule

R-CHOEP 14 with 12x Rituximab is a Chemotherapy combination with monoclonal antibody Small molecule drug developed by German High-Grade Non-Hodgkin's Lymphoma Study Group. It is currently in Phase 3 development for High-grade non-Hodgkin's lymphoma. Also known as: 12 x Rituximab with 8 cycles of standard CHOEP-14.

R-CHOEP 14 with rituximab combines chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone) with the anti-CD20 monoclonal antibody rituximab to kill lymphoma cells through chemotoxicity and antibody-mediated immune destruction.

R-CHOEP 14 with rituximab combines chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone) with the anti-CD20 monoclonal antibody rituximab to kill lymphoma cells through chemotoxicity and antibody-mediated immune destruction. Used for High-grade non-Hodgkin's lymphoma.

At a glance

Generic nameR-CHOEP 14 with 12x Rituximab
Also known as12 x Rituximab with 8 cycles of standard CHOEP-14
SponsorGerman High-Grade Non-Hodgkin's Lymphoma Study Group
Drug classChemotherapy combination with monoclonal antibody
TargetCD20 (rituximab component); DNA/topoisomerase II (chemotherapy components)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

CHOEP is a chemotherapy regimen that damages DNA and disrupts cell division in rapidly dividing lymphoma cells. Rituximab targets CD20 antigen on B-cell lymphomas, triggering antibody-dependent cellular cytotoxicity (ADCC) and direct apoptosis. The combination enhances tumor cell death through complementary mechanisms. The '14' refers to a 14-day cycle schedule.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about R-CHOEP 14 with 12x Rituximab

What is R-CHOEP 14 with 12x Rituximab?

R-CHOEP 14 with 12x Rituximab is a Chemotherapy combination with monoclonal antibody drug developed by German High-Grade Non-Hodgkin's Lymphoma Study Group, indicated for High-grade non-Hodgkin's lymphoma.

How does R-CHOEP 14 with 12x Rituximab work?

R-CHOEP 14 with rituximab combines chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone) with the anti-CD20 monoclonal antibody rituximab to kill lymphoma cells through chemotoxicity and antibody-mediated immune destruction.

What is R-CHOEP 14 with 12x Rituximab used for?

R-CHOEP 14 with 12x Rituximab is indicated for High-grade non-Hodgkin's lymphoma.

Who makes R-CHOEP 14 with 12x Rituximab?

R-CHOEP 14 with 12x Rituximab is developed by German High-Grade Non-Hodgkin's Lymphoma Study Group (see full German High-Grade Non-Hodgkin's Lymphoma Study Group pipeline at /company/german-high-grade-non-hodgkin-s-lymphoma-study-group).

Is R-CHOEP 14 with 12x Rituximab also known as anything else?

R-CHOEP 14 with 12x Rituximab is also known as 12 x Rituximab with 8 cycles of standard CHOEP-14.

What drug class is R-CHOEP 14 with 12x Rituximab in?

R-CHOEP 14 with 12x Rituximab belongs to the Chemotherapy combination with monoclonal antibody class. See all Chemotherapy combination with monoclonal antibody drugs at /class/chemotherapy-combination-with-monoclonal-antibody.

What development phase is R-CHOEP 14 with 12x Rituximab in?

R-CHOEP 14 with 12x Rituximab is in Phase 3.

What are the side effects of R-CHOEP 14 with 12x Rituximab?

Common side effects of R-CHOEP 14 with 12x Rituximab include Neutropenia, Anemia, Thrombocytopenia, Nausea/vomiting, Alopecia, Infusion reactions.

What does R-CHOEP 14 with 12x Rituximab target?

R-CHOEP 14 with 12x Rituximab targets CD20 (rituximab component); DNA/topoisomerase II (chemotherapy components) and is a Chemotherapy combination with monoclonal antibody.

Related